Tranquis Therapeutics

Tranquis Therapeutics is discovering and developing groundbreaking drugs that have the potential to revolutionize the treatment of neurodegenerative and age-related diseases, significantly reducing the burden these conditions impose on patients, families, and societies worldwide. Building on the pioneering neuroimmunology research from the laboratory of Dr. Edgar Engleman, Professor of Medicine at Stanford University, Tranquis Therapeutics' innovative therapies aim to target underlying myeloid immune cell dysfunction associated with a range of neurological disorders.The company’s portfolio includes small molecules capable of crossing the blood-brain barrier, with its lead therapeutic candidates showing encouraging results in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Parkinson’s disease (PD), and age-related cognitive impairment.